Gold Coast, Australia, August 08, 2008 --(PR.com
)-- ARP will provide their Acteev® therapeutic to the Stanford Center on Longevity in order to validate anecdotal evidence that has been previously observed. The study will investigate the short (8 weeks) and longer term (15 month) impact of Acteev® on osteoarthritis symptoms, biomarkers and disease progression in the knee.
The subjects will be tested with the WOMAC osteoarthritis index and visual analogue pain scale. Their usage of NSAIDS for pain relief during the duration of the study will be recorded in order to gauge any continued reliance. To measure changed in macromolecule content and morphological structure of the knee joint Stanford will be utilizing novel MRI techniques, which are more sensitive measures of the OA disease progression than traditional MRI techniques.
The results of the Stanford University study are expected to complement the positive results gained from a comparative study performed earlier in 2008 at the Oklahoma State University. In addition, the study will provide a clearer understanding of the Acteev® mode of action, new potential indications for use, and directions for further studies.
ARP Director Persis Anderson said that “It is great to be working with Stanford and an exciting time for ARP as this study begins just as our current placebo study is finishing. The ongoing compilation of evidence will provide further support for our claims and increase our confidence in engaging potential distribution and marketing partners around the world”.
Dr. Anne Friedlander of the Stanford Center on Longevity said “We are eager to explore the mechanisms of action and possible long-term effects of Acteev® on pain and function in individuals with osteoarthritis. Although we have yet to formally investigate Acteev, the previous short-term studies and anecdotal comments we have obtained from users here at Stanford have been quite positive. We have designed a strong study using novel imaging technology which will provide us with comprehensive data on the efficacy of this new topical cream”.
Acteev® is a registered Trademark of Arthritis Relief Plus Ltd.
About The Stanford Centre on Longevity
The goal of the Stanford Center on Longevity (SCL) is to transform the culture of aging by combining scientific and technological discoveries with swift entrepreneurial action. The SCL links top scholars in their fields with government, business and the media to focus on practical solutions to assure that people arrive in their later years physically fit, mentally sharp, and financially secure. Read about SCL here: http://longevity.stanford.edu/
About Arthritis Relief Plus Ltd.
ARP is a Queensland based, unlisted public company. ARP owns the rights to commercialize Acteev®, a novel formulation that has patent protection pending. ARP is developing the commercial application of Acteev® in a variety of human and animal degenerative joint conditions including osteoarthritis, cervical and lumbar spondylitis.
ARP’s lead product is for the treatment of osteoarthritis and may prove to be the world’s first natural and topical treatment providing long-term results with no known side effects.